Skip to main content

$0.009 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
3 July 2025 at 9:16am
Register to track CPH and receive email alerts.
Subject
CPH Ann: Creso Secures First Purchase Order from Red Light Holland

CPH Ann: Halucenex Update

CPH Ann: Reinstatement to Official Quotation

CPH Ann: Creso's Second Consecutive Quarter of Record Revenue Growth

CPH Ann: Suspension from Official Quotation

CPH Ann: Trading Halt

CPH Ann: Results of Meeting

CPH Ann: Investor Presentation

CPH Ann: Proposed issue of securities - CPH

CPH Ann: Creso Pharma & Red Light Holland to Merge

CPH Ann: Trading Halt

CPH Ann: Creso Pharma completes US OTC dual listing

CPH Ann: Halucenex Expands its Clinical Trials Plans

CPH Ann: Distribution Agreement Expanded to Cover 14 Countries

CPH Ann: Creso & Halucenex welcome Californian Senate Bill

CPH Ann: Halucenex prepares North American market entry

CPH Article: Creso Pharma high on EverBlu Capital

CPH Ann: Proposed issue of Securities - CPH

CPH Ann: Update - Proposed issue of Securities - CPH

CPH Ann: Update - Proposed issue of Securities - CPH

CPH Ann: Update - Proposed issue of Securities - CPH

CPH Ann: Notice of Annual General Meeting/Proxy Form

CPH Ann: Creso Pharma signs Letter of Intent with Polvet

CPH Ann: Creso Launches New Product

CPH Ann: Mernova Awarded Craft Designation with OCS

CPH Ann: Halucenex Secures Additional Pharmaceutical Grade Psilocybin

CPH Ann: Trading Halt

CPH Ann: Pause in Trading

CPH Ann: Halucenex secures agreement with R&D partner Nucro-Technics

CPH Ann: Appendix 2A

CPH Ann: Quarterly Update & Appendix 4C

CPH Ann: Halucenex Update

CPH Ann: Commercial Agreement with Cannabis Queen, South Africa

CPH Ann: ASX Listing Rule 3.13.1 Notice Regarding AGM

CPH Ann: Halucenex Update

CPH Ann: Mernova secures new purchase orders & launches new products

CPH Ann: Creso appoints US executive to lead US entry strategy

CPH Ann: Secondary Trading Notice

CPH Ann: Appendix 2A

CPH Ann: Creso launches three new CBD tea products

CPH Ann: Creso continues positive progress with Halucenex

CPH Ann: Proposed issue of Securities - CPH

CPH Ann: Appendix 2A

CPH Ann: Proposed issue of Securities - CPH

CPH Ann: Creso Receives Firm Commitments to Raise $18M

CPH Article: John Hancock jumps into Creso Pharma; placement upsized

CPH Article: Creso Pharma seeks cash for psychedelic clinical trials

CPH Ann: Trading Halt

CPH Ann: Creso to dual list on US OTC & Halucenex Update

CPH Ann: Appendix 2A

Register to track CPH and receive email alerts.

Similar Companies

CAN
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL